Molecular Hydrogen Therapy for SLE-PAH: Case Report on Immune Marker Modulation.
Ting-Hao Tu, Jeng-Wei Lu, Chun-Hsien Wu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu · In vivo (Athens, Greece) · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In Standard treatments frequently fall short in effectively controlling symptoms, highlighting the need for innovative therapeutic approaches, the patient received daily hydrogen capsules, which resulted in an increased percentage of Tr1 cells, and a decreased percentage of Treg cell subsets, B cell subsets, marginal cell, and plasma cell. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in Standard treatments frequently fall short in effectively controlling symptoms, highlighting the need for innovative therapeutic approaches. The patient received daily hydrogen capsules, which resulted in an increased percentage of Tr1 cells, and a decreased percentage of Treg cell subsets, B cell subsets, marginal cell, and plasma cell.
What the Researchers Studied
The researchers studied Standard treatments frequently fall short in effectively controlling symptoms, highlighting the need for innovative therapeutic approaches.
What Effects Did Molecular Hydrogen Have?
The patient received daily hydrogen capsules, which resulted in an increased percentage of Tr1 cells, and a decreased percentage of Treg cell subsets, B cell subsets, marginal cell, and plasma cell. The authors concluded that this case study highlights the potential efficacy of molecular hydrogen therapy in a patient with SLE-PAD and decompensated right-sided heart failure precipitated by sepsis.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was Standard treatments frequently fall short in effectively controlling symptoms, highlighting the need for innovative therapeutic approaches.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.